Chaihuang-Yishen granule inhibits diabetic kidney disease in rats through blocking TGF-β/Smad3 signaling

PLoS One. 2014 Mar 19;9(3):e90807. doi: 10.1371/journal.pone.0090807. eCollection 2014.

Abstract

Objective: Increasing evidence shows that TGF-β1 is a key mediator in diabetic nephropathy (DN) and induces renal fibrosis positively by Smad3 but negatively by Smad7. However, treatment of DN by blocking the TGF-β/Smad pathway remains limited. The present study investigated the anti-fibrotic effect of a traditional Chinese medicine, Chaihuang-Yishen granule (CHYS), on DN.

Research design and methods: Protective role of CHYS in DN was examined in an accelerated type 1 DN induced by streptozotocin in uninephrectomized Wistar rats. CHYS, at a dose of 0.56 g/kg body weight, was administered by a daily gastric gavage for 20 weeks and the therapeutic effect and potential mechanisms of CHYS on diabetic kidney injury were examined.

Results: Treatment with CHYS attenuated diabetic kidney injury by significantly inhibiting 24-h proteinuria and progressive renal fibrosis including glomerulosclerotic index, tubulointerstitial fibrosis index, and upregulation of extracellular matrix (collagen I, IV, and fibronectin), despite the same levels of blood glucose. Further studies revealed that inhibition of renal fibrosis in CHYS-treated diabetic rats was associated with inhibition of TGF-β1/Smad3 signaling as demonstrated by upregulation of Smad7 but downregulation of TGF-β1, TGF-β receptors, activation of Smad3, and expression of miRNA-21.

Conclusions: CHYS may be a therapeutic agent for DN. CHYS attenuates DN by blocking TGF-β/Smad3-mediated renal fibrosis.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Blood Glucose / metabolism
  • Diabetes Mellitus, Experimental / blood
  • Diabetes Mellitus, Experimental / genetics
  • Diabetes Mellitus, Experimental / pathology
  • Diabetic Nephropathies / drug therapy*
  • Diabetic Nephropathies / genetics
  • Diabetic Nephropathies / metabolism
  • Diabetic Nephropathies / pathology
  • Drugs, Chinese Herbal / pharmacology*
  • Gene Expression Regulation
  • Hypoglycemic Agents / pharmacology*
  • Male
  • Rats
  • Rats, Wistar
  • Receptors, Transforming Growth Factor beta / antagonists & inhibitors*
  • Receptors, Transforming Growth Factor beta / genetics
  • Receptors, Transforming Growth Factor beta / metabolism
  • Signal Transduction / drug effects*
  • Smad3 Protein / antagonists & inhibitors*
  • Smad3 Protein / genetics
  • Smad3 Protein / metabolism
  • Smad7 Protein / agonists
  • Smad7 Protein / genetics
  • Smad7 Protein / metabolism
  • Transforming Growth Factor beta1 / antagonists & inhibitors*
  • Transforming Growth Factor beta1 / genetics
  • Transforming Growth Factor beta1 / metabolism

Substances

  • Blood Glucose
  • Drugs, Chinese Herbal
  • Hypoglycemic Agents
  • Receptors, Transforming Growth Factor beta
  • Smad3 Protein
  • Smad3 protein, rat
  • Smad7 Protein
  • Smad7 protein, rat
  • Transforming Growth Factor beta1
  • yishen

Grants and funding

This work was supported by the National Natural Scientific Foundation of China [grant number: 30973911, 81173422 to PL]; International S&T Cooperation Program of China [grant number: 2011DFA31860 to PL]; Municipal Science and Technology R & D funding of basic research, Shenzhen (Major Program JC201104220290A to HYL); the Research Grant Council of Hong Kong (CUHK5/CRF/09 and CUHK3/CRF/12R to HYL); and the Focused Investment Scheme A and B from the Chinese University of Hong Kong. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.